Skye Bioscience Inc (SKYE)

$0.83 -0.02 (-1.84%)
Market Cap 27.25M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 985,300
Avg Vol 410,630
Day's Range N/A - N/A
Shares Out 32.06M
Stochastic %K 11%
Beta 2.68
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
MissionaryTrader
MissionaryTrader Dec. 24 at 5:04 PM
$SKYE https://x.com/skyebio/status/2003834008090874196?s=20
2 · Reply
Jangalang
Jangalang Dec. 24 at 3:57 AM
$SKYE … These criminals won’t even let you comment on their X page. SCAM.
1 · Reply
Jangalang
Jangalang Dec. 24 at 3:54 AM
$SKYE … What a SCAM POS. I should of sold this trash when I was in profit. This failing company will do their 6th reverse split since I have been holding this for well over five years. Fking SCAMMERS.
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 9:49 PM
$SKYE Non-exclusive Collaboration and License Agreement with Halozyme https://www.rapidticker.com/news/skye-sec-filing-840bfc
0 · Reply
slayer70
slayer70 Dec. 23 at 2:08 PM
$SKYE The FDA just approved novo nordisk wegovy pill for weight loss first oral GLP-1, not sure what it means for this company, but it can't be good.
0 · Reply
passtheball
passtheball Dec. 22 at 9:26 PM
$SKYE Volume has been picking up over the past few trading days.. unfortunately started to randomly tumble down out of nowhere (I haven't seen any news other than the lawsuits).
1 · Reply
NoRiskNoGainEver
NoRiskNoGainEver Dec. 22 at 7:27 PM
$SKYE another r/s. History has to repeat itself time and time again
0 · Reply
YazzJr
YazzJr Dec. 22 at 4:16 PM
$SKYE A buyout of $3 a share would look really tempting at this point. Their market cap is now less than their cash value. Somebody is dumping big time because we are not even halfway through the trading day and it's already twice normal volume. Hoping it's just tax loss selling.
1 · Reply
Fellforit
Fellforit Dec. 21 at 11:59 PM
$SKYE Penny..Penny..Penny....
1 · Reply
1iquid
1iquid Dec. 21 at 10:02 AM
💎 Liquid® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.21- $0.25 Scale out: $0.81-$1.38 Profit Potential : 156% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Latest News on SKYE
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Dec 22, 2025, 9:39 AM EST - 2 days ago

SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

Dec 19, 2025, 2:56 PM EST - 5 days ago

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Dec 10, 2025, 9:37 AM EST - 14 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Dec 8, 2025, 7:11 AM EST - 16 days ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Dec 4, 2025, 10:55 AM EST - 20 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Skye Bioscience to Participate in Upcoming Investment Conferences

Nov 24, 2025, 7:00 AM EST - 4 weeks ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 6 weeks ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 6 weeks ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 7 weeks ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 2 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 2 months ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 2 months ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 2 months ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 2 months ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 3 months ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 3 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 3 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 3 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 3 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 4 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 4 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 4 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 4 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 6 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 7 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 8 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 8 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 8 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 8 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

MissionaryTrader
MissionaryTrader Dec. 24 at 5:04 PM
$SKYE https://x.com/skyebio/status/2003834008090874196?s=20
2 · Reply
Jangalang
Jangalang Dec. 24 at 3:57 AM
$SKYE … These criminals won’t even let you comment on their X page. SCAM.
1 · Reply
Jangalang
Jangalang Dec. 24 at 3:54 AM
$SKYE … What a SCAM POS. I should of sold this trash when I was in profit. This failing company will do their 6th reverse split since I have been holding this for well over five years. Fking SCAMMERS.
0 · Reply
JohnTrack
JohnTrack Dec. 23 at 9:49 PM
$SKYE Non-exclusive Collaboration and License Agreement with Halozyme https://www.rapidticker.com/news/skye-sec-filing-840bfc
0 · Reply
slayer70
slayer70 Dec. 23 at 2:08 PM
$SKYE The FDA just approved novo nordisk wegovy pill for weight loss first oral GLP-1, not sure what it means for this company, but it can't be good.
0 · Reply
passtheball
passtheball Dec. 22 at 9:26 PM
$SKYE Volume has been picking up over the past few trading days.. unfortunately started to randomly tumble down out of nowhere (I haven't seen any news other than the lawsuits).
1 · Reply
NoRiskNoGainEver
NoRiskNoGainEver Dec. 22 at 7:27 PM
$SKYE another r/s. History has to repeat itself time and time again
0 · Reply
YazzJr
YazzJr Dec. 22 at 4:16 PM
$SKYE A buyout of $3 a share would look really tempting at this point. Their market cap is now less than their cash value. Somebody is dumping big time because we are not even halfway through the trading day and it's already twice normal volume. Hoping it's just tax loss selling.
1 · Reply
Fellforit
Fellforit Dec. 21 at 11:59 PM
$SKYE Penny..Penny..Penny....
1 · Reply
1iquid
1iquid Dec. 21 at 10:02 AM
💎 Liquid® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.21- $0.25 Scale out: $0.81-$1.38 Profit Potential : 156% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Multipliers
Multipliers Dec. 20 at 6:58 PM
$SKYE Will probably ,imo, just keep falling until some good news. Might drop below . 50 given nothing significant on the docket for several weeks.
1 · Reply
Sportsfanbar510
Sportsfanbar510 Dec. 20 at 12:59 AM
$SKYE right back where it started before split
0 · Reply
YazzJr
YazzJr Dec. 19 at 8:47 PM
$SKYE Wonder how 5AM is feeling about the half a gillion shares they own of SKYE right about now. I am surprised Managing Partner Andy Schwab still has a job. So far on paper this has to be 5AM biggest Faux Pas ever. Let's see if they can recover but this stock is in free fall. Hopefully it's because of the tax loss selling. We will see but SKYE will be getting a non compliance form from the NASDAQ in 3...2...1...
1 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 19 at 8:01 PM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · DEC 19, 2025 Exp Entry Price: $1.20 - $2.15 Exit Price Target: $2.52 Profit Margin: +110% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
onetimeengineer
onetimeengineer Dec. 19 at 4:08 PM
$SKYE Another loss to add to the stack, very unfortunate!
0 · Reply
InvestInWhatYouKnow
InvestInWhatYouKnow Dec. 18 at 9:39 PM
$SKYE Merry Christmas to my fellow bag holders. I just wanted to give everyone here a .99 shout out today as we hit this new milestone. I'm not sure where this one is headed next year after tax loss selling, but for the most part, I've written it off as a bad investment decision. Owned it since the NMUS days and I have no one to blame but myself for not taking profits when I had the chance a few times. I suppose company hype with SBI-100 and now Nimacimab kept me pretty much engaged and encouraged about all the possibilities, but what we're experiencing now is the second aftermath, so, as a lesson to myself, I decided to just hold my shares to see if they slowly evaporate into nothingness. Investment lessons are costly and with that, some credit to SKYE for re-defining what it means to be All Hat and No Cattle.
1 · Reply
Jangalang
Jangalang Dec. 18 at 6:52 PM
$SKYE … We all been SCAMMED…
0 · Reply
Jangalang
Jangalang Dec. 18 at 6:51 PM
$SKYE … Down 70% in the last year on its way to Bankruptcy. What a pile of trash. 🗑️
0 · Reply
11thestate
11thestate Dec. 18 at 2:36 PM
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $SKYE investors — you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/skye-investor-suit
1 · Reply
Fellforit
Fellforit Dec. 17 at 9:34 PM
$SKYE breaking the 1 $ mark??
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 17 at 3:32 PM
$SKYE Current Stock Price: $1.16 Contracts to trade: $2.5 SKYE Dec 19 2025 Call Entry: $0.05 Exit: $0.07 ROI: 62% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
MissionaryTrader
MissionaryTrader Dec. 17 at 1:44 PM
$SKYE https://ir.skyebioscience.com/sec-filings/all-sec-filings/content/0001873545-25-000004/primary_doc.html
1 · Reply